Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
145.6 USD | -0.21% |
|
+0.17% | -7.08% |
17/06 | J&J: FDA application in lung cancer | CF |
17/06 | Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-7.08% | 35TCr | |
+52.93% | 80TCr | |
+40.98% | 63TCr | |
+17.40% | 32TCr | |
+10.58% | 30TCr | |
+16.42% | 24TCr | |
+2.17% | 23TCr | |
+10.66% | 22TCr | |
+6.24% | 16TCr | |
-4.79% | 16TCr |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at JP Morgan 37th Annual Healthcare conference, Jan-07-2019 through Jan-10-2019